Learn more about our positive long-term MARINA-OLEā„¢ del-desiran (AOC 1001) data including vHOT video and patient testimonials

Noreen Henig, M.D.

Noreen Roth Henig, M.D. brings over 15 years of clinical and development leadership experience in biotechnology companies, in addition to an extensive background in academic research and medicine. Dr. Henig previously served as Chief Medical Officer of Kezar Life Sciences. Prior to that, as Chief Medical Officer of Breath Therapeutics. Breath Therapeutics was acquired by Zambon SpA in July 2019 for up to 500 Million Euros and is now a Zambon Group Company. Dr. Henig also served as Chief Development Officer of ProQR Therapeutics, where she led preclinical and clinical development. ProQR had a successful IPO as a preclinical company in 2014. Earlier in her drug development career, she spent six years at Gilead Sciences, supporting programs in pulmonary and cardiovascular therapeutic areas. Dr. Henig has led multiple Phase 1-Phase 4 programs across therapeutic areas including rare disease, cardiopulmonary, autoimmune, transplant, and ophthalmology. She has experience across all phases of drug development including translational, early and late phase studies, regulatory strategy, medical affairs, and commercial activities. Prior to joining the world of biotechnology, Dr. Henig held several senior academic positions at California Pacific Medical Center and Stanford University School of Medicine. Dr. Henig completed her BA in History of Art at Yale University, completed her M.D. with distinction in immunology from Albert Einstein College of Medicine. She completed training in Internal Medicine at the University of California San Francisco, and Pulmonary and Critical Care and Immunology at the University of Washington.